The professor from University of Texas MD Anderson Cancer Center discussed the FDA approval of lisocabtagene maraleucel.
This content originally appeared on our sister site, Targeted Oncology.
Targeted Oncology spoke with Michael Wang, MD, professor, Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, to learn more about the FDA approval of lisocabtagene maraleucel (liso-cel, Breyanzi).
The liso-cel clinical trial assessed both large B- cell lymphoma and mantle cell lymphoma (MCL). The agent was found to be both effective and tolerable in these indications. In patients with relapsed MCL, the overall response rate was 84% and the complete response (CR) rate was 67%. Wang discussed liso-cel in comparison with brexucabtagene autoleucel (Tecartus).
0:08 | The liso-cel clinical trial were in large-cell lymphoma and mantle cell lymphoma. The large B-cell lymphoma trial has been reported to be very efficacious, and the deciding factor for toxicity is tolerable. During the last ASH meeting, M. Lia Palomba, MD, from Memorial Sloan Kettering Cancer Center, myself, and other colleagues reported the efficacy of liso-cel in relapsed mantle cell lymphoma from 32 patients.
0:43| The overall response rate was 84% with a complete response rate of over 66%. We cannot compare trials across trial, but the efficacy of the brexucabtagene autoleucel can put us into the right context. The overall response rate of was 93% and the CR rate was 67%. So, you can see the CR rates between the 2 products in the 2 separate trials are relatively close. I really think the data on liso-cel relapse in relapsed/refractory mantle cell lymphoma shows good efficacy, and quite has been well-tolerated in relapsed/refractory mantle cell lymphoma.